Animal data suggests this is sufficient for significant mucosal healing in models of inflammatory bowel disease and NSAID-induced injury
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
If you are exploring peptide therapy, work with a qualified clinician who can help you build a plan that matches your physiology and goals
Enrolling 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or higher (without diabetes), SELECT showed that semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 20% over a mean follow-up of nearly 40 months
These treatments can help combat fatigue, support cognitive function, and enhance overall wellness
